Overview

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Dasatinib